The Hungarian Egis Pharma Services, one of the leading generic pharmaceutical companies in Eastern and Central Europe, is now offering drug development and manufacturing services to existing and new pharmaceutical partners, reports Világgazdaság.
Egis, carrying out all its Research & Development and manufacturing 100 percent of its products in Hungary, began building the capabilities behind the new service several years ago through a series of conscious investments:
Over the past decade, it has invested more than HUF 100 billion (EUR 261 million) in Hungary.
In addition to these improvements, investments in the development and production of highly potent active substances have been added to the modernization of active substance production. These are used in the treatment of cancer and rheumatoid arthritis, and have significant biological activity even at very low doses.
Fact Egis is a Hungarian pharmaceutical company. Its activities range from original research and generic development to the manufacture of active pharmaceutical ingredients, finished products, and sales. Discovery research had already begun at the company in the early 1930s. In 1970, a new factory opened in Körmend (western Hungary), and in 1990, a Western European-standard production and research base opened in the 16th district of Budapest. In 2006, Egis embarked on a comprehensive modernization program, renewing its active pharmaceutical ingredient and finished product manufacturing facilities, and expanding its research and development capacity. The company’s new R&D facilities were inaugurated in 2012.
The launch of a new business line, in which Egis will take over the development and manufacture of active substances for both originator and generic companies, marks the next stage in the ongoing development.
These investments will enable them to produce a wide range of high-quality active ingredients faster, more efficiently, cheaper ,and safer.
Csaba Poroszlai, CEO, emphasized that in addition to the specialized equipment and capabilities, one of the biggest advantages is Egis’ vertical integration. In the active pharmaceutical ingredient (API) manufacturing and development segment, this means that they are able to implement all processes from the very first steps of development to large-scale production within the company.
The new business made its debut at one of the world’s largest pharmaceutical trade fairs and events, the CPHI in Barcelona, between October 24 and 26.
Via Világgazdaság, Featured image via Facebook/Országos Tudományos és Innovációs Olimpia